This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Patterson Companies (PDCO) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter 2022 results benefit from strong segmental performance.
Veeva Systems (VEEV) Q2 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both its segments.
Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise
by Zacks Equity Research
Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Phibro (PAHC) Q4 Earnings Match Estimates, Margins Down
by Zacks Equity Research
Phibro (PAHC) sees revenue growth in fourth-quarter fiscal 2021 due to strength in all three segments.
What's in Store for Patterson Companies' (PDCO) Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect improvement at Dental segment.
Is West Pharmaceutical Services (WST) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider West Pharmaceutical Services (WST).
Here is Why Growth Investors Should Buy West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) could produce exceptional returns because of its solid growth attributes.
Align Technology (ALGN) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clear Aligners and Systems & CAD/CAM Services segments drove the top line for Align Technology (ALGN).
Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Medtronic's (MDT) fiscal first-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020.
The Zacks Analyst Blog Highlights: Microsoft, EMCOR, West Pharmaceutical Services, Deere and Texas Instruments
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, EMCOR, West Pharmaceutical Services, Deere and Texas Instruments
Here's Why You Should Add Omnicell (OMCL) to Your Portfolio
by Zacks Equity Research
Omnicell (OMCL) ended the second quarter with better-than-expected results, with the top line registering solid year-over-year growth.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.
LabCorp (LH) Inks Deal to Assess Disparities in Drug Development
by Zacks Equity Research
LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.
Sustainability Trends Boost ESG Investing: 5 Green Picks
by Sreoshi Bera
ESG investing will get a boost from sustainability trends, which calls for investing in Microsoft (MSFT), EMCOR Group (EME), West Pharmaceutical (WST), Deere (DE) & Texas Instruments (TXN).
West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about West Pharmaceutical's (WST) robust proprietary products segment and its continued strength in R&D.
Alcon (ALC) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.
West Pharmaceutical (WST) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum on the back of a solid product portfolio and improving margins. However, forex woes linger.
National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.
Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System.
Haemonetics (HAE) Q1 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Ongoing recovery in businesses, especially Hospital, and the initial Plasma Persona rollouts drove Haemonetics (HAE) fiscal first-quarter revenues.
Inari Medical (NARI) Q2 Earnings Lag, Revenues Top Estimates
by Zacks Equity Research
Inari Medical's (NARI) second-quarter 2021 results benefit from significant revenue growth and gross margin expansion.
STERIS (STE) Q1 Earnings Beat Estimates, 2022 Guidance Up
by Zacks Equity Research
STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.